(NASDAQ: GNLX) Genelux's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Genelux's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GNLX's revenue for 2026 to be $1,479,210,706, with the lowest GNLX revenue forecast at $1,479,210,706, and the highest GNLX revenue forecast at $1,479,210,706. On average, 1 Wall Street analysts forecast GNLX's revenue for 2027 to be $1,479,210,706, with the lowest GNLX revenue forecast at $1,479,210,706, and the highest GNLX revenue forecast at $1,479,210,706.
In 2028, GNLX is forecast to generate $5,818,731,911 in revenue, with the lowest revenue forecast at $5,818,731,911 and the highest revenue forecast at $5,818,731,911.